Healthcare Industry News: Vinorelbine
News Release - March 15, 2006
Novacea Appoints Amar Singh as Chief Commercialization OfficerSOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network)--Mar 15, 2006 -- Novacea, Inc. announced today that Amar Singh has been appointed chief commercialization officer. Mr. Singh joins Novacea from Abraxis Oncology, a proprietary division of American Pharmaceutical Partners, Inc., where he served as vice president of marketing and sales and successfully launched the anticancer agent, ABRAXANE(TM).
At Abraxis, Mr. Singh was responsible for all commercial operations where he built the sales, marketing, business solutions and medical executive teams and directed the successful launch of ABRAXANE. Prior to joining Abraxis, Mr. Singh served as executive director of new product planning, oncology marketing at Hoffmann-La Roche, Inc. where he led the launches of XELODAŽ, a novel oral chemotherapeutic agent for the treatment of metastatic breast cancer, and KYTRILŽ, an anti-nausea agent used in combination with oncolytics.
Mr. Singh holds a M.B.A. degree from New York University, and a B.A. in Economics from the University of North Carolina Chapel Hill.
Novacea, Inc. is a privately held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Novacea's in-licensed product development programs include three clinical-stage oncology product candidates. The Company has one product candidate, DN-101, which is in a Phase 3 clinical trial for prostate cancer and a second product candidate, Vinorelbine oral, which is expected to enter into a registration trial in late 2006 for the treatment of breast or lung cancer. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme. For more information, visit www.novacea.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.